Leukemia最新文献

{"title":"Adding eltrombopag to intensive immunosuppressive therapy for severe aplastic anaemia may help adult patients achieve outcomes similar to paediatric patients","authors":"Bixi Yang, Leyu Wang, Lingling Fu, Miao Chen, Jie Ma, Bing Han","doi":"10.1038/s41375-024-02450-0","DOIUrl":"https://doi.org/10.1038/s41375-024-02450-0","url":null,"abstract":"<p>Aplastic anaemia (AA) is a disorder in which the bone marrow fails to produce enough blood cells [1]. For patients with severe aplastic anaemia (SAA) who are ineligible for haematopoietic stem cell transplantation (HSCT), intensive immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporin A (CsA) is recommended [2]. However, the efficacy of IST alone is higher in children than in adults. Recently, eltrombopag (EPAG) has been proven to enhance the haematologic response to AA treatment [3, 4]. Whether the difference between adults and children still exists during treatment with IST + EPAG remains unclear. To date, no direct comparison of adults and children has been conducted. The aim of this study was to evaluate the differences in treatment efficacy and survival between adults and children treated with different regimens.</p><p>The haematologic response was evaluated in each patient. Among the patients receiving IST alone, the complete response rate (CRR) of adults was lower than that of children at 12 months (31% vs. 48%, P = 0.048), but there was no difference in the overall response rate (ORR) between adults and children at 3, 6, or 12 months (52% <i>vs</i>. 59%, P = 0.426; 69% vs. 74%, P = 0.599; 76% vs. 75%, P = 1.000, respectively). Relatedly, there was no difference in the CRR at 3 and 6 months between the adults and children (3% vs. 11%, P = 0.113; 21% vs. 22%, P = 0.849, respectively). The time to response was 4.3 (IQR 2.9–6.3) months in adults and 3.2 (IQR 2.5–4.0) months in children (P = 0.243), and the time to CR was 8.5 (IQR 6.8–11.0) months in adults and 7.5 (IQR 6.0–10.5) months in children (P = 0.113). Among the patients with IST + EPAG, there was no difference in the ORR between adults and children at 3 or 6 months (67% vs. 64%, P = 0.868; 83% vs. 76%, P = 0.567, respectively), but adults had a higher ORR at 12 months (89% vs. 73%, P = 0.027). There was also no difference in the CRR at 3, 6 and 12 months between the two groups (13% vs. 21%, P = 0.229; 25% <i>vs</i>. 38%, P = 0.124; 54% vs. 50%, P = 0.614, respectively; Fig. 1). The time to response was 3.0 (IQR 2.8–3.3) months in adults and 2.5 (IQR 1.9–3.9) months in children (P = 0.361). Moreover, the time to CR was 6.0 (IQR 3.0–8.3) months for adults and 3.9 (IQR 2.5–5.7) months for children (P = 0.478).</p>","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":"252 1","pages":""},"PeriodicalIF":11.4,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142678565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clonal hematopoiesis in large granular lymphocytic leukemia","authors":"Naomi Kawashima, Carmelo Gurnari, Carlos Bravo-Perez, Yasuo Kubota, Simona Pagliuca, Luca Guarnera, Nakisha D. Williams, Arda Durmaz, Arooj Ahmed, Danai Dima, Fauzia Ullah, Hetty E. Carraway, Abhay Singh, Valeria Visconte, Jaroslaw P. Maciejewski","doi":"10.1038/s41375-024-02460-y","DOIUrl":"https://doi.org/10.1038/s41375-024-02460-y","url":null,"abstract":"<p>Past studies described occasional patients with myeloid neoplasms (MN) and coexistent large granular lymphocytic leukemia (LGLL) or T-cell clonopathy of unknown significance (TCUS), which may represent expansion of myeloid clonal hematopoiesis (CH) as triggers or targets of clonal cytotoxic T cell reactions. We retrospectively analyzed 349 LGLL/TCUS patients, 672 MN patients, and 1443 CH individuals to establish the incidence, genetic landscape, and clinical phenotypes of CH in LGLL. We identified 8% of cases overlapping with MN, while CH was found in an additional 19% of cases (CH + /LGLL) of which <i>TET2</i> (23%) and <i>DNMT3A</i> (14%) were the most common. In MN cohort, 3% of cases showed coexistent LGLL. The incidence of CH in LGLL was exceedingly higher than age-matched CH controls (<i>P</i> &lt; 0.0001). By multivariate analysis, the presence of CH in LGLL (<i>P</i> = 0.026) was an independent risk factor for cytopenia in addition to older age (<i>P</i> = 0.003), splenomegaly (<i>P</i> = 0.015) and <i>STAT3/5B</i> mutations (<i>P</i> = 0.001). CH + /LGLL cases also showed a higher progression rate to MN than CH-/LGLL (10% <i>vs</i>. 2% at 5 years; <i>P</i> = 0.02). A close relationship between CH and LGLL suggests that cytopenia in LGLL may be not only related to LGLL but be also secondary to coexisting clonal cytopenia of unclear significance.</p>","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":"3 1","pages":""},"PeriodicalIF":11.4,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142684396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The co-receptor Neuropilin-1 enhances proliferation in inv(16) acute myeloid leukemia via VEGF signaling","authors":"Mahesh Hegde, Mohd H. Ahmad, Roger Mulet Lazaro, Mayumi Sugita, Rui Li, Kai Hu, Claudia Gebhard, Monica L. Guzman, John H. Bushweller, Lihua J. Zhu, Michael Brehm, Scot A. Wolfe, Ruud Delwel, Lucio H. Castilla","doi":"10.1038/s41375-024-02471-9","DOIUrl":"https://doi.org/10.1038/s41375-024-02471-9","url":null,"abstract":"<p>Oncogenic programs regulate the proliferation and maintenance of cancer stem cells, and can define pharmacologic dependencies. In acute myeloid leukemia (AML) with the chromosome inversion 16 (inv(16)), the fusion oncoprotein CBFβ::MYH11 regulates pathways associated with leukemia stem cell activity. Here we demonstrate that expression of Neuropilin-1 (NRP1) is regulated by the fusion oncoprotein, and promotes AML expansion. Mechanistically, we show that the <i>NRP1</i> locus has open chromatin in inv(16) AML, and that CBFβ::MYH11 modulates the local function of the transcription factors ERG, GATA2 and RUNX1 to sustain NRP1 levels. We found that ERG activates <i>NRP1</i> expression, and that CBFβ::MYH11 knockdown represses ERG expression, thereby allowing the repressive activity of GATA2/RUNX1 at three <i>NRP1</i> enhancers. Functionally, we demonstrate that NRP1 enhances the expansion of leukemic cells in vitro and in mice, and that this activity is dependent on its VEGFR-associated FV/FVIII domain. Finally, we show that treatment with VEGF inhibitor axitinib reduces AML cell growth and delays median leukemia latency in vivo. Our findings reveal that the NRP1/VEGF axis mediates proliferation in inv(16) AML blasts, and suggest that targeting NRP1 function could be promising in combination AML therapy.</p>","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":"253 1","pages":""},"PeriodicalIF":11.4,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142684427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global patterns of leukemia by subtype, age, and sex in 185 countries in 2022","authors":"Dagrun S. Daltveit, Eileen Morgan, Murielle Colombet, Eva Steliarova-Foucher, Karima Bendahhou, Rafael Marcos-Gragera, Zheng Rongshou, Alexandra Smith, Hui Wei, Isabelle Soerjomataram","doi":"10.1038/s41375-024-02452-y","DOIUrl":"https://doi.org/10.1038/s41375-024-02452-y","url":null,"abstract":"<p>In 2022, leukemia ranked as the second most common hematological malignancy after non-Hodgkin lymphoma worldwide. However, updated global estimates of leukemia incidence by subtype are unavailable. We estimated leukemia incidences for different leukemia subtypes by country, world region, and human developmental index using data from the Cancer Incidence in Five Continents databases combined with the GLOBOCAN 2022 estimates of leukemia in 185 countries. We estimated sex-specific age-standardized rates (ASRs) per 100 000 for children (0–19 years) and adults (20+ years). In adults, the most common leukemia worldwide was AML (males: 38%, ASR = 3·1; females: 43%, ASR = 2·4), followed by CLL (males: 28%, ASR = 2·2; females: 24%, ASR = 1·3). In very high HDI countries, the ASR of CLL was higher than the ASR of AML among males (5·2 versus 4·3, respectively) and similar among females (2·9 and 3·0, respectively). In children, the most common leukemia was ALL (boys: 70%, ASR = 2·4; girls: 68%, ASR = 1·8) followed by AML (boys: 22%, ASR = 0·76; girls: 25%, ASR = 0·65). ALL proportions varied across world sub-regions from 57 to 78% among boys, and from 49 to 80% among girls. Our findings suggest clear geographical patterns of leukemia subtypes in adults and children. Further research into underlying causes that explain these variations is needed to support cancer control strategies for prevention and plan national healthcare needs.</p>","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":"2 1","pages":""},"PeriodicalIF":11.4,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142673884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polycomb group protein Mel18 inhibits hematopoietic stem cell self-renewal through repressing the transcription of self-renewal and proliferation genes","authors":"Wenjie Cai, Xicheng Liu, Sergio Barajas, Shiyu Xiao, Sasidhar Vemula, Hongxia Chen, Yuxia Yang, Christopher Bochers, Danielle Henley, Sheng Liu, Yuzhi Jia, Michelle Hong, Tiffany M. Mays, Maegan L. Capitano, Huiping Liu, Peng Ji, Zhonghua Gao, Diego Pasini, Jun Wan, Feng Yue, Leonidas C. Platanias, Rongwen Xi, Sisi Chen, Yan Liu","doi":"10.1038/s41375-024-02462-w","DOIUrl":"https://doi.org/10.1038/s41375-024-02462-w","url":null,"abstract":"<p>Polycomb group (PcG) proteins play important roles in hematopoietic stem cell (HSC) self-renewal. Mel18 and Bmi1 are homologs of the PCGF subunit within the Polycomb repressive complex 1 (PRC1). Bmi1 (PCGF4) enhances HSC self-renewal and promotes terminal differentiation. However, the role of Mel18 (PCGF2) in hematopoiesis is not fully understood and how Mel18 regulates gene transcription in HSCs remains elusive. We found that acute deletion of <i>Mel18</i> in the hematopoietic compartment significantly increased the frequency of functional HSCs in the bone marrow. Furthermore, we demonstrate that Mel18 inhibits HSC self-renewal and proliferation. RNA-seq studies revealed that HSC self-renewal and proliferation gene signatures are enriched in <i>Mel18</i>^{<i>−/−</i>} hematopoietic stem and progenitors (HSPCs) compared to <i>Mel18</i>^<i>+/+</i> HSPCs. Notably, ATAC-seq revealed increased chromatin accessibility at genes important for HSC self-renewal, whereas CUT&amp;RUN showed decreased enrichment of H2AK119ub1 at genes important for proliferation, leading to increased expression of both <i>Hoxb4</i> and <i>Cdk4</i> in <i>Mel18</i>^{<i>−/−</i>} HSPCs. Thus, we demonstrate that Mel18 inhibits hematopoietic stem cell self-renewal through repressing the transcription of genes important for HSC self-renewal and proliferation.</p>","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":"40 1","pages":""},"PeriodicalIF":11.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142673902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study","authors":"Guillermo Ortí, Christophe Peczynski, William Boreland, Maeve O’Reilly, Malte von Bonin, Adriana Balduzzi, Caroline Besley, Krzysztof Kalwak, Samppa Ryhänen, Tayfun Güngör, Robert F. Wynn, Peter Bader, Stephan Mielke, Didier Blaise, Persis Amrolia, Ibrahim Yakoub-Agha, Friso Calkoen, Maria-Luisa Schubert, Victoria Potter, Herbert Pichler, Nicolaus Kröger, Mi Kwon, Henrik Sengeloev, Anna Torrent, Yves Chalandon, Gwendolyn van Gorkom, Christian Koenecke, Charlotte Graham, Helene Schoemans, Ivan Moiseev, Olaf Penack, Zinaida Peric","doi":"10.1038/s41375-024-02467-5","DOIUrl":"https://doi.org/10.1038/s41375-024-02467-5","url":null,"abstract":"<p>In patients diagnosed with B-acute lymphoblastic leukemia (B-ALL) or B-non-Hodgkin’s lymphoma (B-NHL) relapsing after allogeneic stem cell transplantation (allo-HCT), it is a standard practice to perform anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. When collected from the patient after allo-HCT, the produced CAR-T cells are likely to be donor T-cell-derived, creating unknown safety risks due to their potential allo-reactivity. We therefore performed an EBMT registry-based study on the incidence of graft-versus-host disease (GvHD) in this setting. We included 257 allo-HCT patients (<i>n</i> = 172 ≥ 18 years) with B-ALL or B-NHL, treated with anti-CD19 CAR T-cells (tisagenlecleucel <i>n</i> = 184, brexucabtagene autoleucel <i>n</i> = 43 and axicabtagene ciloleucel <i>n</i> = 30), between 2018 and 2022. Three patients developed aGvHD, whereas 6 patients developed cGvHD after CAR T-cell. The 100-day cumulative incidence (CI) of new aGvHD was 1.6% and the 12-month CI of new cGvHD was 2.8%. The 1-year GvHD relapse-free survival and non-relapse mortality were 52.1% and 4.7%, respectively. Last, with a median follow up of 18.8 months, the 1-year overall survival was 76.8%. In summary, the GvHD rate in allo-HCT patients treated with CAR T-cell therapy is relatively low. Our data support the view that GvHD is not a major safety issue in this setting.</p>","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":"74 1","pages":""},"PeriodicalIF":11.4,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142673890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucose uptake capacity of leukaemia cells in vitro correlates with response to induction therapy in acute myeloid leukaemia.","authors":"Suqi Deng, Juan Du, Kexiu Huang, Robert Peter Gale, Danqi Pan, Lu Wang, Junjie Wei, Xue Zheng, Ying Xu, Shengqian Xie, Wei Zhou, Weihao Xiao, Bo Liu, Zhiyang Chen, Zhenyu Ju, Hui Zeng","doi":"10.1038/s41375-024-02469-3","DOIUrl":"10.1038/s41375-024-02469-3","url":null,"abstract":"","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms","authors":"Ian M. Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Naveen Pemmaraju, Tapan Kadia, Lucia Masarova, Koichi Takahashi, Michael Andreeff, Alexandre Bazinet, Hui Yang, Rashmi Kanagal, Sherry Pierce, Meghan Meyer, Xuelin Huang, Guillermo Garcia-Manero","doi":"10.1038/s41375-024-02457-7","DOIUrl":"https://doi.org/10.1038/s41375-024-02457-7","url":null,"abstract":"<p>Patients with myelodysplastic neoplasms (MDS) who progress on hypomethylating agents have poor outcomes [1,2,3]. There are no standard treatment approaches in this setting; while high-dose chemotherapy followed by allogeneic stem cell transplant remains a curative option for higher-risk MDS, advanced age and significant comorbidities preclude this approach for many patients [4]. In these cases, novel therapies are urgently needed.</p><p>Programmed cell death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) are upregulated in hypomethylating agent failure MDS [5]. PD-L1 on the surface of MDS cells binds to PD-1 on T cells, facilitating immune evasion [6]. Similarly, CTLA4 on T cells binds to B7 on MDS cells, stifling T-cell receptor activation and contributing to immune escape [7]. These findings provide a rationale for assessing PD-1 and CTLA4 blockade in MDS following hypomethylating agent exposure [7]. Ipilimumab and nivolumab are fully human IgG1k monoclonal antibodies that target CTLA4 and PD-1, respectively [8, 9]. Both monotherapy and combination immunotherapy approaches are safe and effective in solid tumors and lymphomas; however, their safety and efficacy in relapsed or refractory MDS remains unclear.</p>","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":"25 1","pages":""},"PeriodicalIF":11.4,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142645944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9","authors":"Vignesh Krishnamoorthy, John Daly, Jimmy Kim, Lidia Piatnitca, Katie A. Yuen, Bhoj Kumar, Mehrnoush Taherzadeh Ghahfarrokhi, Tom Q. T. Bui, Parastoo Azadi, Ly P. Vu, Simon Wisnovsky","doi":"10.1038/s41375-024-02454-w","DOIUrl":"https://doi.org/10.1038/s41375-024-02454-w","url":null,"abstract":"<p>Immunotherapy has demonstrated promise as a treatment for acute myeloid leukemia (AML). However, there is still an urgent need to identify new molecules that inhibit the immune response to AML. Most prior research in this area has focused on protein-protein interaction interfaces. While carbohydrates also regulate immune recognition, the role of cell-surface glycans in driving AML immune evasion is comparatively understudied. The Siglecs, for example, are an important family of inhibitory, glycan-binding signaling receptors that have emerged as prime targets for cancer immunotherapy in recent years. In this study, we find that AML cells express ligands for the receptor Siglec-9 at high levels. Integrated CRISPR genomic screening and clinical bioinformatic analysis identified ST3GAL4 as a potential driver of Siglec-9 ligand expression in AML. Depletion of ST3GAL4 by CRISPR-Cas9 knockout (KO) dramatically reduced the expression of Siglec-9 ligands in AML cells. Mass spectrometry analysis of cell-surface glycosylation in ST3GAL4 KO cells revealed that Siglec-9 primarily binds N-linked sialoglycans on these cell types. Finally, we found that ST3GAL4 KO enhanced the sensitivity of AML cells to phagocytosis by Siglec-9-expressing macrophages. This work reveals a novel axis of immune evasion and implicates ST3GAL4 as a possible target for immunotherapy in AML.</p>","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":"51 1","pages":""},"PeriodicalIF":11.4,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142645945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia.","authors":"Qiangqiang Shao, Jedrzej Wykretowicz, Nan Hu, Karan Bedi, Mohamed Rizk, Isabella A Malek, Surinder Kumar, David B Lombard, Kerby Shedden, David Scott, Sami N Malek","doi":"10.1038/s41375-024-02472-8","DOIUrl":"https://doi.org/10.1038/s41375-024-02472-8","url":null,"abstract":"","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142623310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}